How does the noncleavable linker benefit the anti-MIgG(Fc)Fab-N-DM1 ADC in cancer therapy?

The noncleavable linker in the anti-MIgG(Fc)Fab-N-DM1 ADC enhances the stability of the ADC in the bloodstream, ensuring that the cytotoxic drug DM1 remains attached until the ADC is internalized by cancer cells. This property reduces premature drug release and minimizes off-target toxicity, improving therapeutic efficacy.

Can the anti-MIgG(Fc)Fab-N-DM1 ADC be used in flow cytometry?

Yes, the anti-MIgG(Fc)Fab-N-DM1 ADC can be utilized in flow cytometry to identify and quantify ADC binding to cells expressing the target antigen. It's essential to validate the specific conditions and antibody concentration for each experimental setup.

What types of research applications is the anti-MIgG(Fc)Fab-N-DM1 ADC most suited for?

The anti-MIgG(Fc)Fab-N-DM1 ADC is particularly suited for preclinical research in oncology, including studies on drug delivery efficiency, cytotoxicity assays, and mechanism of action investigations in cancer cell lines or animal models.

How is the efficacy of the anti-MIgG(Fc)Fab-N-DM1 ADC monitored in experimental settings?

Efficacy can be monitored through various in vitro assays such as cell viability tests, apoptosis assays, and in vivo studies measuring tumor regression in suitable animal models. These assessments help determine the ADC's therapeutic potential and optimal dosing regimen.

What impact does glycosylation in the Fc region have on the function of the anti-MIgG(Fc)Fab-N-DM1 ADC?

Glycosylation at the Fc region enhances the ADC's stability and its interaction with Fc receptors on immune cells. This interaction promotes immune-mediated activities such as ADCC, enhancing the ADC's overall antitumor efficacy.

Home
Products
Anti-Ab ADCs
IgG Fc
anti-MIgG(Fc)Fab-N-DM1 ADC

anti-MIgG(Fc)Fab-N-DM1 ADC (CAT#: ADC-AA-031)

This ADC product is comprised of a Fab fragment of an anti-mouse IgG Fc specific polyclonal antibody conjugated via a noncleavable linker to DM1. The antibody portion is a Fab fragment of a secondary antibody and the drug portion, DM1, is a cytotoxic small molecule which binds to tubulins, interrupts microtubule dynamics, and induces cell death. This product displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening mouse monoclonal antibodies as ADC candidates.

ADC Target
ADC Antibody
ADC Linker
ADC payload drug

Name
IgG Fc

Overview
The fragment crystallizable region (Fc region) is composed of the constant region of the two heavy chains that form the IgG molecule. The Fc region of IgG bears a highly conserved N-glycosylation site. Glycosylation of the Fc fragment is essential for Fc receptor-mediated activity. Fc binds to various cell receptors and complement proteins thus mediating different physiological effects of antibodies, such as opsonization, antibody dependent cellular cytotoxicity (ADCC), degranulation of mast cells, basophils, eosinophils and other processes.

Overview
Fab fragment of anti-mouse IgG Fc specific polyclonal antibody

Species Reactivity
Mouse

Name
Noncleavable linkers

Description
Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.

Name
DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)

Description
Derived from Maytansinoid,a group of cytotoxins structurally similar to rifamycin, geldanamycin, and ansatrienin. The eponymous natural cytotoxic agent maytansine is a 19-member lactam (ansa
macrolide) structure originally isolated from the Ethiopian shrub Maytenus ovatus. Maytansinoids can bind to tubulin at or near the vinblastine-binding site, which interfere the formation of microtubules and depolymerize already formed microtubules, inducing mitotic arrest in the intoxicated cells.

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-AA-031. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

The anti-MIgG(Fc)Fab-N-DM1 ADC has been a game changer in our antibody development, offering powerful tubulin interaction without compromising safety.

Excellent

The safety profile and efficacy of the anti-MIgG(Fc)Fab-N-DM1 ADC make it an indispensable tool for early-stage antibody development.

Excellent

The specificity and stability of the anti-MIgG(Fc)Fab-N-DM1 ADC have tremendously improved our selection process for potent monoclonal antibodies.

Excellent

We rely heavily on the anti-MIgG(Fc)Fab-N-DM1 ADC for its precise action on microtubules, which is crucial for our cytotoxicity studies. It's a top-tier research tool.

Excellent

The non-toxic nature of this ADC without a primary antibody is a major advantage, allowing for safe and efficient pre-screening of various antibodies.

Q: 1: How does the noncleavable linker benefit the anti-MIgG(Fc)Fab-N-DM1 ADC in cancer therapy?
A: The noncleavable linker in the anti-MIgG(Fc)Fab-N-DM1 ADC enhances the stability of the ADC in the bloodstream, ensuring that the cytotoxic drug DM1 remains attached until the ADC is internalized by cancer cells. This property reduces premature drug release and minimizes off-target toxicity, improving therapeutic efficacy.
Q: 2: Can the anti-MIgG(Fc)Fab-N-DM1 ADC be used in flow cytometry?
A: Yes, the anti-MIgG(Fc)Fab-N-DM1 ADC can be utilized in flow cytometry to identify and quantify ADC binding to cells expressing the target antigen. It's essential to validate the specific conditions and antibody concentration for each experimental setup.
Q: 3: What types of research applications is the anti-MIgG(Fc)Fab-N-DM1 ADC most suited for?
A: The anti-MIgG(Fc)Fab-N-DM1 ADC is particularly suited for preclinical research in oncology, including studies on drug delivery efficiency, cytotoxicity assays, and mechanism of action investigations in cancer cell lines or animal models.
Q: 4: How is the efficacy of the anti-MIgG(Fc)Fab-N-DM1 ADC monitored in experimental settings?
A: Efficacy can be monitored through various in vitro assays such as cell viability tests, apoptosis assays, and in vivo studies measuring tumor regression in suitable animal models. These assessments help determine the ADC's therapeutic potential and optimal dosing regimen.
Q: 5: What impact does glycosylation in the Fc region have on the function of the anti-MIgG(Fc)Fab-N-DM1 ADC?
A: Glycosylation at the Fc region enhances the ADC's stability and its interaction with Fc receptors on immune cells. This interaction promotes immune-mediated activities such as ADCC, enhancing the ADC's overall antitumor efficacy.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload

CAT#	Product Name	Linker	Payload
ADC-AA-053	Protein A-MMAF ADC		MMAF (Monomethyl auristatin F)
ADC-AA-027	anti-MIgG(Fc)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-048	Protein G-VC-MMAE ADC	VC (valine-citrulline)	MMAE (Monomethyl auristatin E)
ADC-AA-051	Protein G-Duocarmycin ADC		Duocarmycins
ADC-AA-021	anti-MIgG(Fc)-C-MMAE ADC	Cleavable linkers	MMAE (Monomethyl auristatin E)

CAT#	Product Name	Linker	Payload
ADC-AA-018	anti-HIgG(Fab)-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-009	anti-HIgG(Fc)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-019	anti-MIgG(Fc)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-026	anti-MIgG(Fc)-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-034	anti-RIgG(HL)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)

CAT#	Product Name	Linker	Payload
ADC-AA-018	anti-HIgG(Fab)-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-050	Protein G-MCC-DM1 ADC	MCC (Maleimidomethyl cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-572	Anti-ERBB2 (Trastuzumab-Fab)-SPP-DM1 ADC	SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-008	anti-HIgG(Fc)-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-015	anti-HIgG(Fc)Fab-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.